The ICNMD 2024 presentation explored whether other sources of bias were adequately controlled in evaluating ataluren plus standard of care (SoC) on loss of ambulation for patients in the STRIDE Registry
International Congress on Neuromuscular Diseases (ICNMD)
The International Congress on Neuromuscular Diseases (ICNMD) provides updates on neuromuscular disorders and helps attendees expand their global connections and collaborations.
Please select the resource of interest below:
|
Congress
Topic
Type
Year
This symposium, presented at ICNMD 2024, provides an overview of clinical trial and real-world data for nonsense mutation Duchenne muscular dystrophy (nmDMD) and highlights the importance of continuous care
Access PTC abstracts, infographics, posters and symposia presented at international meetings in the fields of pediatric neurology, cognitive neuroscience and movement disorders, such as the Muscular Dystrophy Association (MDA) Annual Clinical & Scientific Conference, the Child Neurological Society (CNS) Annual Meeting, the World Muscle Society (WMS) Annual Congress, and International Congress on Neuromuscular Diseases (ICNMD).
Registration conditions vary by country; please consult local prescribing information and/or the Summary of Product Characteristics prior to prescribing any products.
MED-ALL-DFZ-2500002 v-2 | April 2026
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-ATLN-2500006 | September 2025
MED-ALL-DMD-2200043 | June 2025